Abstract
At present, the number of diabetes mellitus (DM) patients has exceeded 537 million worldwide, and this number continues to increase. Type 1 diabetes (T1D) is caused by the autoimmune destruction of β-cells, whereas type 2 diabetes (T2D) is caused by a hostile metabolic environment that leads to β-cell exhaustion and dysfunction. The prevalence of DM type 1 and type 2 is widespread and results in fatality without treatment. As of now, first-line medications for diabetes address hyperglycemia and insulin resistance. Owing to this, there is a need to develop advanced therapies that can either protect or replace lost β-cells with stem-cell-derived β-like cells or engineered islet-like clusters. Recently, stem cells (SCs) have been considered to be renewable cell sources in the treatment of diabetes and the development of insulin-producing cells. Clinicians used adult mesenchymal stem cells (Lavinsky et al., Proceedings of the National Academy of Sciences of the United States of America 95:2920–5, 1998) and embryonic stem cells (ESC) to improve patients’ condition; however, they faced ethical challenges and the danger of developing tumors in patients. Induced pluripotent stem cell (iPSC)-based genetically modified stem cell therapy is the way to fix these problems, together with diabetes medicines available now. Patient- or disease-specific cell lines are permitted under iPSC. An improved iPSC or SC-islet differentiation generates cells that secrete insulin, which makes it possible for autologous diabetic cell replacement and disease modeling in vitro. As SC-islets are limitless, they can be used for individualized therapy and to overcome the drawbacks of donor islets. Therefore, this chapter focuses on the potential of islet engineering, diabetes cells, and their therapeutic potential among the iPSC-derived progenitors. These studies on stem cells and regenerative medicine may result in new treatments for diabetes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abdelalim, E. M. (2021). Modeling different types of diabetes using human pluripotent stem cells. Cellular and Molecular Life Sciences, 78(6), 2459–2483. https://doi.org/10.1007/s00018-020-03710-9
Abdelalim, E. M., Bonnefond, A., Bennaceur-Griscelli, A., & Froguel, P. (2014). Pluripotent stem cells as a potential tool for disease modelling and cell therapy in diabetes. Stem Cell Reviews and Reports, 10(3), 327–337. https://doi.org/10.1007/s12015-014-9503-6
Al-Maskari, A. Y., Al-Maskari, M. Y., & Al-Sudairy, S. (2011). Oral manifestations and complications of Diabetes mellitus: A review. Sultan Qaboos University Medical Journal, 11(2), 179–186.
Al-Maweri, S. A., Ismail, N. M., Ismail, A. R., & Al-Ghashm, A. (2013). Prevalence of oral mucosal lesions in patients with type 2 diabetes attending hospital universiti sains Malaysia. Malays J Med Sci, 20(4), 39–46.
American Diabetes, A. (2021). 2. Classification and diagnosis of Diabetes: Standards of medical Care in Diabetes-2021. Diabetes Care, 44(Suppl 1), S15–S33. https://doi.org/10.2337/dc21-S002
Atkinson, M. A. (2012). The pathogenesis and natural history of type 1 diabetes. Cold Spring Harb Perspect Med, 2(11), a007641. https://doi.org/10.1101/cshperspect.a007641
Augsornworawat, P., Maxwell, K. G., Velazco-Cruz, L., & Millman, J. R. (2020). Single-cell transcriptome profiling reveals beta cell maturation in stem cell-derived islets after transplantation. Cell Reports, 32(8), 108067. https://doi.org/10.1016/j.celrep.2020.108067
Balboa, D., Saarimaki-Vire, J., Borshagovski, D., Survila, M., Lindholm, P., Galli, E., et al. (2018). Insulin mutations impair beta-cell development in a patient-derived iPSC model of neonatal diabetes. eLife, 7, e38519. https://doi.org/10.7554/eLife.38519
Blair, M. (2016). Diabetes mellitus review. Urologic Nursing, 36(1), 27–36.
Brozzi, F., Nardelli, T. R., Lopes, M., Millard, I., Barthson, J., Igoillo-Esteve, M., et al. (2015). Cytokines induce endoplasmic reticulum stress in human, rat and mouse beta cells via different mechanisms. Diabetologia, 58(10), 2307–2316. https://doi.org/10.1007/s00125-015-3669-6
Campbell-Thompson, M., Fu, A., Kaddis, J. S., Wasserfall, C., Schatz, D. A., Pugliese, A., et al. (2016). Insulitis and beta-cell mass in the natural history of type 1 Diabetes. Diabetes, 65(3), 719–731. https://doi.org/10.2337/db15-0779
Carrero, J. A., Ferris, S. T., & Unanue, E. R. (2016). Macrophages and dendritic cells in islets of Langerhans in diabetic autoimmunity: A lesson on cell interactions in a mini-organ. Current Opinion in Immunology, 43, 54–59. https://doi.org/10.1016/j.coi.2016.09.004
Chen, C., Cohrs, C. M., Stertmann, J., Bozsak, R., & Speier, S. (2017). Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis. Mol Metab, 6(9), 943–957. https://doi.org/10.1016/j.molmet.2017.06.019
Chen, S., Du, K., & Zou, C. (2020). Current progress in stem cell therapy for type 1 diabetes mellitus. Stem Cell Research & Therapy, 11(1), 275. https://doi.org/10.1186/s13287-020-01793-6
Coomans de Brachene, A., Dos Santos, R. S., Marroqui, L., Colli, M. L., Marselli, L., Mirmira, R. G., et al. (2018). IFN-alpha induces a preferential long-lasting expression of MHC class I in human pancreatic beta cells. Diabetologia, 61(3), 636–640. https://doi.org/10.1007/s00125-017-4536-4
Coppieters, K. T., Dotta, F., Amirian, N., Campbell, P. D., Kay, T. W., Atkinson, M. A., et al. (2012). Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. The Journal of Experimental Medicine, 209(1), 51–60. https://doi.org/10.1084/jem.20111187
Cuypers, M., Leijssen, M., Bakker-van Gijssel, E. J., Pouls, K. P. M., Mastebroek, M. M., Naaldenberg, J., et al. (2021). Patterns in the prevalence of diabetes and incidence of diabetic complications in people with and without an intellectual disability in Dutch primary care: Insights from a population-based data-linkage study. Primary Care Diabetes, 15(2), 372–377. https://doi.org/10.1016/j.pcd.2020.11.012
D'Amour, K. A., Bang, A. G., Eliazer, S., Kelly, O. G., Agulnick, A. D., Smart, N. G., et al. (2006). Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nature Biotechnology, 24(11), 1392–1401. https://doi.org/10.1038/nbt1259
de Klerk, E., & Hebrok, M. (2021). Stem cell-based clinical trials for Diabetes mellitus. Front Endocrinol (Lausanne), 12, 631463. https://doi.org/10.3389/fendo.2021.631463
Diabetes. (2021). Available from: https://www.who.int/health-topics/diabetes#tab=tab_1.
DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018). Type 1 diabetes. Lancet, 391(10138), 2449–2462. https://doi.org/10.1016/S0140-6736(18)31320-5
Dominguez-Bendala, J., Qadir, M. M. F., & Pastori, R. L. (2019). Pancreatic progenitors: There and Back again. Trends in Endocrinology and Metabolism, 30(1), 4–11. https://doi.org/10.1016/j.tem.2018.10.002
Eizirik, D. L., Pasquali, L., & Cnop, M. (2020). Pancreatic beta-cells in type 1 and type 2 diabetes mellitus: Different pathways to failure. Nature Reviews. Endocrinology, 16(7), 349–362. https://doi.org/10.1038/s41574-020-0355-7
Enderami, S. E., Mortazavi, Y., Soleimani, M., Nadri, S., Biglari, A., & Mansour, R. N. (2017). Generation of insulin-producing cells from human-induced pluripotent stem cells using a stepwise differentiation protocol optimized with platelet-rich plasma. Journal of Cellular Physiology, 232(10), 2878–2886. https://doi.org/10.1002/jcp.25721
Fenske, W., & Allolio, B. (2012). Clinical review: Current state and future perspectives in the diagnosis of diabetes insipidus: A clinical review. The Journal of Clinical Endocrinology and Metabolism, 97(10), 3426–3437. https://doi.org/10.1210/jc.2012-1981
Foulis, A. K., Liddle, C. N., Farquharson, M. A., Richmond, J. A., & Weir, R. S. (1986). The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: A 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia, 29(5), 267–274. https://doi.org/10.1007/BF00452061
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., et al. (2020). Pathophysiology of type 2 Diabetes mellitus. International Journal of Molecular Sciences, 21(17), 6275. https://doi.org/10.3390/ijms21176275
Giorgetti, A., Montserrat, N., Aasen, T., Gonzalez, F., Rodriguez-Piza, I., Vassena, R., et al. (2009). Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell, 5(4), 353–357. https://doi.org/10.1016/j.stem.2009.09.008
Gotthardt, M. (2011). A therapeutic insight in beta-cell imaging? Diabetes, 60(2), 381–382. https://doi.org/10.2337/db10-1591
Hamano, K., Nakadaira, I., Suzuki, J., & Gonai, M. (2014). N-terminal fragment of probrain natriuretic peptide is associated with diabetes microvascular complications in type 2 diabetes. Vascular Health and Risk Management, 10, 585–589. https://doi.org/10.2147/VHRM.S67753
Haque, M., Das, J. K., Xiong, X., & Song, J. (2019). Targeting stem cell-derived tissue-associated regulatory T cells for type 1 Diabetes immunotherapy. Current Diabetes Reports, 19(10), 89. https://doi.org/10.1007/s11892-019-1213-7
Harris, A. G., Letourneau, L. R., & Greeley, S. A. W. (2018). Monogenic diabetes: The impact of making the right diagnosis. Current Opinion in Pediatrics, 30(4), 558–567. https://doi.org/10.1097/MOP.0000000000000643
Hattersley, A. T., & Patel, K. A. (2017). Precision diabetes: Learning from monogenic diabetes. Diabetologia, 60(5), 769–777. https://doi.org/10.1007/s00125-017-4226-2
Hering, B. J., Clarke, W. R., Bridges, N. D., Eggerman, T. L., Alejandro, R., Bellin, M. D., et al. (2016). Phase 3 trial of transplantation of human islets in type 1 Diabetes complicated by severe hypoglycemia. Diabetes Care, 39(7), 1230–1240. https://doi.org/10.2337/dc15-1988
Hosokawa, Y., Toyoda, T., Fukui, K., Baden, M. Y., Funato, M., Kondo, Y., et al. (2017). Insulin-producing cells derived from ‘induced pluripotent stem cells’ of patients with fulminant type 1 diabetes: Vulnerability to cytokine insults and increased expression of apoptosis-related genes. J Diabetes Investig. https://doi.org/10.1111/jdi.12727
Hrvatin, S., O'Donnell, C. W., Deng, F., Millman, J. R., Pagliuca, F. W., DiIorio, P., et al. (2014). Differentiated human stem cells resemble fetal, not adult, beta cells. Proceedings of the National Academy of Sciences of the United States of America, 111(8), 3038–3043. https://doi.org/10.1073/pnas.1400709111
Hu, F. B. (2011). Globalization of diabetes: The role of diet, lifestyle, and genes. Diabetes Care, 34(6), 1249–1257. https://doi.org/10.2337/dc11-0442
Huangfu, D., Osafune, K., Maehr, R., Guo, W., Eijkelenboom, A., Chen, S., et al. (2008). Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nature Biotechnology, 26(11), 1269–1275. https://doi.org/10.1038/nbt.1502
IDF Diabetes Atlas. (2009). Available from: https://diabetesatlas.org/resources/?gclid=Cj0KCQjw08aYBhDlARIsAA_gb0fpvIF4U-lVyapljiZs4ergUvx9VA0F9oC0y7rlSIJrbX1UhwG66ygaAj3aEALw_wcB.
IDF Diabetes Atlas. (2011). Available from: https://diabetesatlas.org/atlas/fifth-edition/.
IDF Diabetes Atlas. (2015). Available from: https://www.diabetesatlas.org/upload/resources/previous/files/7/IDF%20Diabetes%20Atlas%207th.pdf.
IDF Diabetes Atlas. 10th Edition (2021). Available from: https://diabetesatlas.org/atlas/tenth-edition/.
Ilegems, E., Dicker, A., Speier, S., Sharma, A., Bahow, A., Edlund, P. K., et al. (2013). Reporter islets in the eye reveal the plasticity of the endocrine pancreas. Proceedings of the National Academy of Sciences of the United States of America, 110(51), 20581–20586. https://doi.org/10.1073/pnas.1313696110
Indurkar, M. S., Maurya, A. S., & Indurkar, S. (2016). Oral manifestations of diabetes. Clin Diabetes, 34(1), 54–57. https://doi.org/10.2337/diaclin.34.1.54
In't Veld, P. (2011). Insulitis in human type 1 diabetes: The quest for an elusive lesion. Islets, 3(4), 131–138. https://doi.org/10.4161/isl.3.4.15728
Jeon, K., Lim, H., Kim, J. H., Thuan, N. V., Park, S. H., Lim, Y. M., et al. (2012). Differentiation and transplantation of functional pancreatic beta cells generated from induced pluripotent stem cells derived from a type 1 diabetes mouse model. Stem Cells and Development, 21(14), 2642–2655. https://doi.org/10.1089/scd.2011.0665
Jiang, J., Au, M., Lu, K., Eshpeter, A., Korbutt, G., Fisk, G., et al. (2007). Generation of insulin-producing islet-like clusters from human embryonic stem cells. Stem Cells, 25(8), 1940–1953. https://doi.org/10.1634/stemcells.2006-0761
Kahn, C. R., & Lecture, B. (1994). Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes, 43(8), 1066–1084. https://doi.org/10.2337/diab.43.8.1066
Karamanou, M., Protogerou, A., Tsoucalas, G., Androutsos, G., & Poulakou-Rebelakou, E. (2016). Milestones in the history of diabetes mellitus: The main contributors. World Journal of Diabetes, 7(1), 1–7. https://doi.org/10.4239/wjd.v7.i1.1
Kharroubi, A. T., & Darwish, H. M. (2015). Diabetes mellitus: The epidemic of the century. World Journal of Diabetes, 6(6), 850–867. https://doi.org/10.4239/wjd.v6.i6.850
Kishore, S., De Franco, E., Cardenas-Diaz, F. L., Letourneau-Freiberg, L. R., Sanyoura, M., Osorio-Quintero, C., et al. (2020). A non-coding disease modifier of pancreatic agenesis identified by genetic correction in a patient-derived iPSC line. Cell Stem Cell, 27(1), 137–146 e6. https://doi.org/10.1016/j.stem.2020.05.001
Krogvold, L., Wiberg, A., Edwin, B., Buanes, T., Jahnsen, F. L., Hanssen, K. F., et al. (2016). Insulitis and characterisation of infiltrating T cells in surgical pancreatic tail resections from patients at onset of type 1 diabetes. Diabetologia, 59(3), 492–501. https://doi.org/10.1007/s00125-015-3820-4
Kroon, E., Martinson, L. A., Kadoya, K., Bang, A. G., Kelly, O. G., Eliazer, S., et al. (2008). Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nature Biotechnology, 26(4), 443–452. https://doi.org/10.1038/nbt1393
Kudva, Y. C., Ohmine, S., Greder, L. V., Dutton, J. R., Armstrong, A., De Lamo, J. G., et al. (2012). Transgene-free disease-specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes. Stem Cells Translational Medicine, 1(6), 451–461. https://doi.org/10.5966/sctm.2011-0044
Latres, E., Finan, D. A., Greenstein, J. L., Kowalski, A., & Kieffer, T. J. (2019). Navigating two roads to glucose normalization in Diabetes: Automated insulin delivery devices and cell therapy. Cell Metabolism, 29(3), 545–563. https://doi.org/10.1016/j.cmet.2019.02.007
Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T. M., Schiff, R., et al. (1998). Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proceedings of the National Academy of Sciences of the United States of America, 95(6), 2920–2925. https://doi.org/10.1073/pnas.95.6.2920
Lithovius, V., Saarimaki-Vire, J., Balboa, D., Ibrahim, H., Montaser, H., Barsby, T., et al. (2021). SUR1-mutant iPS cell-derived islets recapitulate the pathophysiology of congenital hyperinsulinism. Diabetologia, 64(3), 630–640. https://doi.org/10.1007/s00125-020-05346-7
Lopez-Yrigoyen, M., Yang, C. T., Fidanza, A., Cassetta, L., Taylor, A. H., McCahill, A., et al. (2019). Genetic programming of macrophages generates an in vitro model for the human erythroid island niche. Nature Communications, 10(1), 881. https://doi.org/10.1038/s41467-019-08705-0
Ma, X., Lu, Y., Zhou, Z., Li, Q., Chen, X., Wang, W., et al. (2022). Human expandable pancreatic progenitor-derived β cells ameliorate diabetes. Science Advances, 8(8), eabk1826. https://doi.org/10.1126/sciadv.abk1826
Ma, S., Viola, R., Sui, L., Cherubini, V., Barbetti, F., & Egli, D. (2018). Beta cell replacement after gene editing of a neonatal Diabetes-causing mutation at the insulin locus. Stem Cell Reports, 11(6), 1407–1415. https://doi.org/10.1016/j.stemcr.2018.11.006
Maehr, R., Chen, S., Snitow, M., Ludwig, T., Yagasaki, L., Goland, R., et al. (2009). Generation of pluripotent stem cells from patients with type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America, 106(37), 15768–15773. https://doi.org/10.1073/pnas.0906894106
Marroqui, L., Dos Santos, R. S., Op de Beeck, A., Coomans de Brachene, A., Marselli, L., Marchetti, P., et al. (2017). Interferon-alpha mediates human beta cell HLA class I overexpression, endoplasmic reticulum stress and apoptosis, three hallmarks of early human type 1 diabetes. Diabetologia, 60(4), 656–667. https://doi.org/10.1007/s00125-016-4201-3
Maxwell, K. G., Augsornworawat, P., Velazco-Cruz, L., Kim, M. H., Asada, R., Hogrebe, N. J., et al. (2020). Gene-edited human stem cell-derived beta cells from a patient with monogenic diabetes reverse preexisting diabetes in mice. Science Translational Medicine, 12(540). https://doi.org/10.1126/scitranslmed.aax9106
Millman, J. R., Xie, C., Van Dervort, A., Gurtler, M., Pagliuca, F. W., & Melton, D. A. (2016). Generation of stem cell-derived beta-cells from patients with type 1 diabetes. Nature Communications, 7, 11463. https://doi.org/10.1038/ncomms11463
Minagawa, A., Yoshikawa, T., Yasukawa, M., Hotta, A., Kunitomo, M., Iriguchi, S., et al. (2018). Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy. Cell Stem Cell, 23(6), 850–858 e4. https://doi.org/10.1016/j.stem.2018.10.005
Murakami, T., Fujimoto, H., & Inagaki, N. (2021). Non-invasive Beta-cell Imaging: Visualization, Quantification, and Beyond. Front Endocrinol (Lausanne), 12, 714348. https://doi.org/10.3389/fendo.2021.714348
Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T., & Yamanaka, S. (2008). Generation of mouse induced pluripotent stem cells without viral vectors. Science, 322(5903), 949–953. https://doi.org/10.1126/science.1164270
Padgett, L. E., Broniowska, K. A., Hansen, P. A., Corbett, J. A., & Tse, H. M. (2013). The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis. Annals of the New York Academy of Sciences, 1281, 16–35. https://doi.org/10.1111/j.1749-6632.2012.06826.x
Padhi, S., Nayak, A. K., & Behera, A. (2020). Type II diabetes mellitus: A review on recent drug based therapeutics. Biomedicine & Pharmacotherapy, 131, 110708. https://doi.org/10.1016/j.biopha.2020.110708
Pagliuca, F. W., Millman, J. R., Gurtler, M., Segel, M., Van Dervort, A., Ryu, J. H., et al. (2014). Generation of functional human pancreatic beta cells in vitro. Cell, 159(2), 428–439. https://doi.org/10.1016/j.cell.2014.09.040
Qi, Z., Shen, Y., Yanai, G., Yang, K., Shirouzu, Y., Hiura, A., et al. (2010). The in vivo performance of polyvinyl alcohol macro-encapsulated islets. Biomaterials, 31(14), 4026–4031. https://doi.org/10.1016/j.biomaterials.2010.01.088
Reed, J. C., & Herold, K. C. (2015). Thinking bedside at the bench: The NOD mouse model of T1DM. Nature Reviews. Endocrinology, 11(5), 308–314. https://doi.org/10.1038/nrendo.2014.236
Saarimaki-Vire, J., Balboa, D., Russell, M. A., Saarikettu, J., Kinnunen, M., Keskitalo, S., et al. (2017). An activating STAT3 mutation causes neonatal Diabetes through premature induction of pancreatic differentiation. Cell Reports, 19(2), 281–294. https://doi.org/10.1016/j.celrep.2017.03.055
Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., et al. (2019). Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the international Diabetes federation Diabetes Atlas, 9(th) edition. Diabetes Research and Clinical Practice, 157, 107843. https://doi.org/10.1016/j.diabres.2019.107843
Sapra, A. (2022). Diabetes mellitus. Treasure Island (FL).
Sequiera, G. L., Srivastava, A., Sareen, N., Yan, W., Alagarsamy, K. N., Verma, E., et al. (2022). Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases. Science Advances, 8(14), eabl4370. https://doi.org/10.1126/sciadv.abl4370
Shang, L., Hua, H., Foo, K., Martinez, H., Watanabe, K., Zimmer, M., et al. (2014). Beta-cell dysfunction due to increased ER stress in a stem cell model of Wolfram syndrome. Diabetes, 63(3), 923–933. https://doi.org/10.2337/db13-0717
Shapiro, A. M., Lakey, J. R., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., et al. (2000). Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. The New England Journal of Medicine, 343(4), 230–238. https://doi.org/10.1056/NEJM200007273430401
Shapiro, A. M., Ricordi, C., Hering, B. J., Auchincloss, H., Lindblad, R., Robertson, R. P., et al. (2006). International trial of the Edmonton protocol for islet transplantation. The New England Journal of Medicine, 355(13), 1318–1330. https://doi.org/10.1056/NEJMoa061267
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010). Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice, 87(1), 4–14. https://doi.org/10.1016/j.diabres.2009.10.007
Silveira, P. A., & Grey, S. T. (2006). B cells in the spotlight: Innocent bystanders or major players in the pathogenesis of type 1 diabetes. Trends in Endocrinology and Metabolism, 17(4), 128–135. https://doi.org/10.1016/j.tem.2006.03.006
Smid, M., Wilting, S. M., Uhr, K., Rodríguez-González, F. G., de Weerd, V., Prager-Van der Smissen, W. J. C., et al. (2019). The circular RNome of primary breast cancer. Genome Research, 29(3), 356–366. https://doi.org/10.1101/gr.238121.118
Stock, A. A., Manzoli, V., De Toni, T., Abreu, M. M., Poh, Y. C., Ye, L., et al. (2020). Conformal coating of stem cell-derived islets for beta cell replacement in type 1 Diabetes. Stem Cell Reports, 14(1), 91–104. https://doi.org/10.1016/j.stemcr.2019.11.004
Sui, L., Danzl, N., Campbell, S. R., Viola, R., Williams, D., Xing, Y., et al. (2018). Beta-cell replacement in mice using human type 1 Diabetes nuclear transfer embryonic stem cells. Diabetes, 67(1), 26–35. https://doi.org/10.2337/db17-0120
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861–872. https://doi.org/10.1016/j.cell.2007.11.019
Teo, A. K., Windmueller, R., Johansson, B. B., Dirice, E., Njolstad, P. R., Tjora, E., et al. (2013). Derivation of human induced pluripotent stem cells from patients with maturity onset diabetes of the young. The Journal of Biological Chemistry, 288(8), 5353–5356. https://doi.org/10.1074/jbc.C112.428979
Toyoda, T., Mae, S., Tanaka, H., Kondo, Y., Funato, M., Hosokawa, Y., et al. (2015). Cell aggregation optimizes the differentiation of human ESCs and iPSCs into pancreatic bud-like progenitor cells. Stem Cell Research, 14(2), 185–197. https://doi.org/10.1016/j.scr.2015.01.007
van Belle, T. L., Coppieters, K. T., & von Herrath, M. G. (2011). Type 1 diabetes: Etiology, immunology, and therapeutic strategies. Physiological Reviews, 91(1), 79–118. https://doi.org/10.1152/physrev.00003.2010
Wang, L., Li, X., Wang, Z., Bancks, M. P., Carnethon, M. R., Greenland, P., et al. (2021). Trends in prevalence of Diabetes and control of risk factors in Diabetes among US adults, 1999-2018. JAMA, 326(8), 704–716. https://doi.org/10.1001/jama.2021.9883
Wang, X., Sterr, M., Ansarullah, Burtscher, I., Bottcher, A., Beckenbauer, J., et al. (2019). Point mutations in the PDX1 transactivation domain impair human beta-cell development and function. Mol Metab, 24, 80–97. https://doi.org/10.1016/j.molmet.2019.03.006
Wareham, N. J., & O'Rahilly, S. (1998). The changing classification and diagnosis of diabetes. New classification is based on pathogenesis, not insulin dependence. BMJ, 317(7155), 359–360. https://doi.org/10.1136/bmj.317.7155.359
Wilcox, G. (2005). Insulin and insulin resistance. Clinical Biochemist Reviews, 26(2), 19–39.
Willcox, A., Richardson, S. J., Bone, A. J., Foulis, A. K., & Morgan, N. G. (2009). Analysis of islet inflammation in human type 1 diabetes. Clinical and Experimental Immunology, 155(2), 173–181. https://doi.org/10.1111/j.1365-2249.2008.03860.x
Wisel, S. A., Braun, H. J., & Stock, P. G. (2016). Current outcomes in islet versus solid organ pancreas transplant for beta-cell replacement in type 1 diabetes. Current Opinion in Organ Transplantation, 21(4), 399–404. https://doi.org/10.1097/MOT.0000000000000332
Xiao, X., Fischbach, S., Song, Z., Gaffar, I., Zimmerman, R., Wiersch, J., et al. (2016). Transient suppression of TGFbeta receptor signaling facilitates human islet transplantation. Endocrinology, 157(4), 1348–1356. https://doi.org/10.1210/en.2015-1986
Yamanaka, S. (2012). Induced pluripotent stem cells: Past, present, and future. Cell Stem Cell, 10(6), 678–684. https://doi.org/10.1016/j.stem.2012.05.005
Yao, D., & Brownlee, M. (2010). Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes, 59(1), 249–255. https://doi.org/10.2337/db09-0801
Yoon, J. W., & Jun, H. S. (2005). Autoimmune destruction of pancreatic beta cells. American Journal of Therapeutics, 12(6), 580–591. https://doi.org/10.1097/01.mjt.0000178767.67857.63
Yoshihara, E., O'Connor, C., Gasser, E., Wei, Z., Oh, T. G., Tseng, T. W., et al. (2020). Immune-evasive human islet-like organoids ameliorate diabetes. Nature, 586(7830), 606–611. https://doi.org/10.1038/s41586-020-2631-z
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318(5858), 1917–1920. https://doi.org/10.1126/science.1151526
Zaharia, O. P., Strassburger, K., Strom, A., Bönhof, G. J., Karusheva, Y., Antoniou, S., et al. (2019). Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: A 5-year follow-up study. The Lancet Diabetes and Endocrinology, 7(9), 684–694. https://doi.org/10.1016/s2213-8587(19)30187-1
Zhang, Q., Gonelle-Gispert, C., Li, Y., Geng, Z., Gerber-Lemaire, S., Wang, Y., et al. (2022). Islet encapsulation: New developments for the treatment of type 1 Diabetes. Frontiers in Immunology, 13, 869984. https://doi.org/10.3389/fimmu.2022.869984
Zheng, Y. L. (2016). Some ethical concerns about human induced pluripotent stem cells. Science and Engineering Ethics, 22(5), 1277–1284. https://doi.org/10.1007/s11948-015-9693-6
Zhong, F., & Jiang, Y. (2019). Endogenous pancreatic beta cell regeneration: A potential strategy for the recovery of beta cell deficiency in Diabetes. Front Endocrinol (Lausanne), 10, 101. https://doi.org/10.3389/fendo.2019.00101
Zhou, Z., Zhu, X., Huang, H., Xu, Z., Jiang, J., Chen, B., et al. (2022). Recent Progress of research regarding the applications of stem cells for treating Diabetes mellitus. Stem Cells and Development, 31(5–6), 102–110. https://doi.org/10.1089/scd.2021.0083
Acknowledgment
We would like to thank Mr. M. Vijayaraman for their English language editing.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Chhetri, D., Amarnath, R.N., Samal, S., Palaniyandi, K., Gnanasampanthapandian, D. (2023). Diabetes Mellitus and iPSC-Based Therapy. In: Noor, R. (eds) Advances in Diabetes Research and Management. Springer, Singapore. https://doi.org/10.1007/978-981-19-0027-3_10
Download citation
DOI: https://doi.org/10.1007/978-981-19-0027-3_10
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-0026-6
Online ISBN: 978-981-19-0027-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)